RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populations

Expert Review of Clinical Immunology

Volumn 13, Issue 12, 2017, Pages 1107-1119

  Wasserman, Richard L ^a   Greener, Benjamin N ^b   Mond, James ^c  

^a Allergy/Immunology Research Center of North Texas   (United States)

^b Pharmaceutical Product Development   (United States)

^c Chief Medical and Scientific Officer ADMA Biologics Inc   (United States)

Author keywords

Anti RSV; influenza; IVIG; primary immunodeficiency disease; respiratory syncytial virus; RI 002; ribavirin; RSV IVIG

Indexed keywords

ANTIVIRUS AGENT; IMMUNOGLOBULIN; NEUTRALIZING ANTIBODY; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RI 002; VIRUS ANTIBODY;

ANTIBODY TITER; ARTICLE; COTTON RAT; DISEASE MODEL; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; INFLUENZA; NONHUMAN; PRECLINICAL STUDY; PROPHYLAXIS; SUPPLEMENTATION; ANIMAL; CLINICAL TRIAL (TOPIC); EXPERT WITNESS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PROCEDURES; RAT; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SIGMODONTINAE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; EXPERT TESTIMONY; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOTHERAPY; RATS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SIGMODONTINAE;

EID: 85031504216     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1080/1744666X.2017.1389647     Document Type: Article

References (58)

1. Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol. 2005;94(5 Suppl 1):S1–S63.
2. Ballow M., Optimizing immunoglobulin treatment for patients with primary immunodeficiency disease to prevent pneumonia and infection incidence: review of the current data. Ann Allergy Asthma Immunol. 2013;111(6 Suppl):S2–5.
3. Orange JS, Grossman WJ, Navickis RJ, et al. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137(1):21–30.
4. Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125(6):1354–1360 e1354.
5. Kainulainen L, Vuorinen T, Rantakokko-Jalava K, et al. Recurrent and persistent respiratory tract viral infections in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol. 2010;126(1):120–126.
6. Jolles S., Subclinical infection and dosing in primary immunodeficiencies. Clin Exp Immunol. 2014;178(Suppl 1):67–69.
7. Resch B, Manzoni P, Lanari M. Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes. Paediatr Respir Rev. 2009;10(3):148–153.
8. Lanari M, Vandini S, Capretti MG, et al. Respiratory syncytial virus infections in infants affected by primary immunodeficiency. J Immunol Res. 2014;1–6.
9. FDA.gov [Internet]. Silver Spring (MD): U.S. Department of Health and Human Services. Cited. 2016 Sep 29. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=640&showFR=1&subpartNode=21:7.0.1.1.7.10FDA 21 CFR 640 subpart J.
10. Mikolajczyk MG, Concepcion NF, Wang T, et al. Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immunoglobulin intravenous preparations. Clin Diagn Lab Immunol. 2004;11(6):1158–1164.
11. Orange JS, Du W, Falsey AR. Therapeutic immunoglobulin selected for high antibody titer to RSV also contains high antibody titers to other respiratory viruses. Front Immunol. 2015;6:431.
12. Bonagura VR, Marchlewski R, Cox A, et al. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol. 2008;122(1):210–212.
13. Orange JS, Belohradsky BH, Berger M, et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol. 2012;169(2):172–181.
14. Jesenak M, Banovcin P, Jesenakova B, et al. Pulmonary manifestations of primary immunodeficiency disorders in children. Front Pediatr. 2014;2:77.
15. The IMpact RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531–537.
16. Parnes C, Guillermin J, Habersang R. Palivizumab outcomes registry study. Palivizumab Prophylaxis of Respiratory Syncytial Virus Disease in 2000–2001: Results from the Palivizumab Outcomes Registry. Pediatr Pulmonol. 2003;35(6):484–489.
17. Frogel M, Nerwen C, Cohen A, et al. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol. 2008;28(7):511–517.
18. Ohmit SE, Moler FW, Monto AS, et al. Ribavirin utilization and clinical effectiveness in children hospitalized with respiratory syncytial virus infection. J Clin Epidemiol. 1996;49(9):963–967.
19. Englund JA, Piedra PA, Whimbey E. Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients. Am J Med. 1997;102(3A):61–70.
20. Krinzman S, Basgoz N, Kradin R, et al. Respiratory syncytial virus-associated infections in adult recipients of solid organ transplants. J Heart Lung Transplant. 1998;17(2):202–210.
21. Ghosh S, Champlin RE, Ueno NT, et al. Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins. Bone Marrow Transplant. 2001;28(3):271–275.
22. Turner TL, Kopp BT, Paul G, et al. Respiratory syncytial virus: current and emerging treatment options. Clinicoecon Outcomes Res. 2014;6:217–225.
23. Lewinsohn DM, Bowden RA, Mattson D, et al. Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation. Antimicrob Agents Chemother. 1996;40(11):2555–2557.
24. RespiGam® [package insert]. Gaithersburg, MD: MedImmune, Inc. 2000.
25. Groothuis JR, Simoes EA, Levin MJ, et al. Prophylactic administation of respiratory syncytial virus immune globulin to high risk infants and young children. Nejm. 1993;329:1524–1530.
26. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997;99(1):93–99.
27. Simoes EA, Groothius JR, Tristram DA, et al. Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high-risk children. J Pediatr. 1996;129:214–219.
28. American Academy of Pediatrics. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics. 1998;102:1211–1216.
29. DeVincenzo JP, Hirsch RL, Fuentes RJ, et al. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation–a compassionate use experience. Bone Marrow Transplant. 2000;25(2):161–165.
30. Robinson RF, Nahata MC. Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection. Am J Health-Syst Pharm. 2000;57:260–264.
31. Simoes EA, Sondheimer HM, Top FH, et al. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. Cardiac Study Group J Pediatr. 1998;133(4):492–499.
32. Shah JN, Chemaly RF. Management of RSV infection in adult recipients of hematopoietic stem cell transplantation. Blood. 2011;117(10):2755–2763.
33. Falsey A, Walsh E, Mond J, Polyclonal human intravenous immune globulin (IGIV) with high-levels of RSV neutralizing antibodies: a summary of animal and human studies. Poster session presented at: Annual Conference of the Canadian Blood and Marrow Transplant Group; 2014 Jun 11–2014; Halifax, NS.
34. Falsey A, Walsh E, Mond JJ, Polyclonal human intravenous immune globulin (IGIV) with high- levels of RSV neutralizing antibodies: a summary of animal and human studies. Poster session presented at: Clinical Immunology Society Annual Meeting; 2014 April 10–13; Baltimore, MD
35. Falsey A, Koval C, Khorana M, et al. Use of high titer RSV immunoglobulin (RI-001-RSV IVIG) in immunocompromised adults. Poster session presented at: Infectious Disease Week; 2013 Oct 2–6; Chicago, IL.
36. Pohl C, Green M, Wald ER, et al. Respiratory syncytial virus infections in pediatric liver transplant recipients. J Infect Dis. 1992;165(1):166–169.
37. Prince GA, Jensen AB, Horswood RL, et al. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Path. 1978;93(3):771–792.
38. Boukhvalova MS, Prince GA, Blanco JC. The cotton rat model of respiratory viral infections. Biologicals. 2009;37(3):152–159.
39. Niewiesk S, Prince G. Diversifying animal models: the use of hispid cotton rats in infectious diseases. Lab Anim. 2002;36:357–372.
40. Boukhvalova MS, Yim KC, Kuhn KH, et al. Age-related differences in pulmonary cytokine response to respiratory syncytial virus infection: modulation by anti-inflammatory and antiviral treatment. J Infect Dis. 2007;195:511–518.
41. Curtis SJ, Ottolini MG, Porter DD, et al. Age-dependent replication of respiratory syncytial virus in the cotton rat. Exp Biol Med. 2002;227:799–802.
42. Johnson RA, Pricne GA, Suffin SC. Respiratory syncytial virus infection in cyclophosphamide-treated cotton rats. J Infect Dis. 1982;176:1215–1224.
43. Ottolini MG, Porter DD, Hemming VG, et al. Effectiveness of RSVIG prophylaxis and therapy of respiratory syncytial virus in an immunosuppressed animal model. Bone Marrow Transplant. 1999;24:41–45.
44. Prince GA, Hemming VG, Horswood RL. Immunoprophylaxis and immunotherapy of RSV in the cotton rat. Virus Res. 1985;3:193–206.
45. Siber GR, Leombruno D, Leszczynski J, et al. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis. 1994;169:1368–1373.
46. Prince GA, Horswood RL, Chanock RM. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol. 1985;55(3):517–520.
47. Borchers AT, Chang C, Gershwin ME, et al. Respiratory syncytial virus–a comprehensive review. Clin Rev Allergy Immunol. 2013;45(3):331–379.
48. Mond J, Gilbert B, Falsey A, High titer anti-RSV Polyclonal antibody (RI-002) prevents infection with palivizumab resistant RSV in cotton rats and achieves greater neutralizing anti-RSV activity as compared to palivizumab. Poster session presented at: AAAAI Annual Meeting. 2015 Mar 4–6. Los Angeles, CA.
49. Mond J, DeMario L, Tumpey T, et al. Protective levels of neutralizing antibodies to influenza are present in an IVIG (RI-002) containing standardized and elevated levels of neutralizing antibodies to RSV and can protect influenza infected cotton rats. Poster session presented at: CIS Annual Meeting. 2016 Apr 14–17. Boston, MA.
50. Boukhvalova M, Blanco JC, Falsey AR, et al. Treatment with novel RSV Ig RI-002 controls viral replication and reduces pulmonary damage in immunocompromised Sigmodon hispidus. Bone Marrow Transplant. 2016;51(1):119–126.
51. Gilbert BE, Protection against palivizumab resistant RSV with an IVIG containing high titer anti-RSV neutralizing antibodies. Poster session presented at: 2nd International Primary Immunodeficiencies Congress. 2015 Nov 5–6. Budapest, Hungary.
52. Mond J, Falsey A, Boukhvalova M, et al. Treatment of normal and immune suppressed cotton rats with IVIG containing high neutralizing titer anti-RSV antibody. Poster session presented at: 9th International Respiratory Syncytial Virus Symposium; 2014 Nov 9–13; Cape Town, South Africa.
53. Coudeville L, Bailleux F, Riche B, et al. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol. 2010;10:18.
54. Hobson D, Curry RL, Beare AS, et al. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972;70(4):767–777.
55. Wasserman RL, Lumry W, Harris J, 3rd, et al. Efficacy, safety, and pharmacokinetics of a new 10 % liquid intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses in subjects with primary immunodeficiency disease. J Clin Immunol. 2016;36(6):590–599.
56. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291(5503):484–486.
57. Grossman A, Mond J, Grossman J, inventor; ADMA biologics, assignee. composition and methods for the treatment of immunodeficiency. United States patent US 9,107,906. 2015 Aug 18.
58. Mond J, Du W, Kobayashi R, et al. Results of a Phase III trial in patients with PIDD using an IVIG containing high titer neutralizing antibody to respiratory syncytial virus (RSV). Poster session presented at: AAAAI Annual Meeting. 2015 Feb 20–24. Houston, TX.